Seeking Alpha

Morgan Stanley starts Mallinckrodt at Buy

  • "Unlike commoditized generics, controlled substances enjoy limited competition," Morgan Stanley's Christopher Caponetti notes, initiating coverage of Mallinckrodt (MNK +4%) at Buy.
  • The company's position as "a leader in controlled substance generics" should pay off as prices rise over time.
  • Price target is $60, representing upside of 15% from Tuesday's close.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)